Mathew Golding
Research Subjects
Mathew Golding has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Peter Marples
Diamond Light Source
12 shared publications - Anu V. Chandran
Diamond Light Source, Harwell Science and Innovation Campus
11 shared publications - Frank von Delft
Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK
10 shared publications - Lizbé Koekemoer
Centre for Medicines Discovery University of Oxford Old Road Campus, Roosevelt Drive OX3 7DQ Headington UK
9 shared publications - Michael Fairhead
ASAP Discovery Consortium ASAP Discovery Discovery University of Oxford ASAP D
9 shared publications Charlotte Chinn
8 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (41) , 20097-20117
A resource-efficient structure-based workflow for fragment progression enables parallel hit discovery and validation of functionally diverse modulators of NCS-1 protein–protein interactions
A data-driven, automation-assisted, customizable framework for fragment-to-hit progression that directly delivers structurally validated hit series primed for rapid SAR exploration and exploits high-throughput crystallography at synchrotrons.
- 28 October 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (41) , 20097-20117
Open AccessA resource-efficient structure-based workflow for fragment progression enables parallel hit discovery and validation of functionally diverse modulators of NCS-1 protein–protein interactions
A data-driven, automation-assisted, customizable framework for fragment-to-hit progression that directly delivers structurally validated hit series primed for rapid SAR exploration and exploits high-throughput crystallography at synchrotrons.
- Open Access
- 6 August 2026
- Published by Springer Nature
Dengue virus NS5 RdRp protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Dengue virus (DENV) NS5 RdRp protease using the Creoptix Wave system. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged DENV NS5 RdRp protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- 6 August 2026
- Published by Springer Nature
Open AccessDengue virus NS5 RdRp protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Dengue virus (DENV) NS5 RdRp protease using the Creoptix Wave system. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged DENV NS5 RdRp protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- Open Access
- 6 August 2026
- Published by Springer Nature
Zika virus NS5 RdRp protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Zika virus (ZIKV) NS5 RdRp protease using the Creoptix Wave system. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged ZIKV NS5 RdRp protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- 6 August 2026
- Published by Springer Nature
Open AccessZika virus NS5 RdRp protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Zika virus (ZIKV) NS5 RdRp protease using the Creoptix Wave system. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged ZIKV NS5 RdRp protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- Open Access
- 24 July 2026
- Published by Springer Nature
Coxsackievirus A16 2A protease binding assay for compound screening using grating-coupled interferometry v2
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against coxsackievirus A16 (CVA16) 2A protease using the Creoptix Wave system. CVA16 2A protease is used as a surrogate for the related enterovirus A71 (EV-A71) 2A protease in the pan-enteroviral drug discovery efforts by our collaborator, the AI-Driven Structure-Enabled Antiviral Platform (ASAP) Discovery Center, and was chosen as the target for OpenBind's first data release package. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged CVA16 2A protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- 24 July 2026
- Published by Springer Nature
Open AccessCoxsackievirus A16 2A protease binding assay for compound screening using grating-coupled interferometry v2
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against coxsackievirus A16 (CVA16) 2A protease using the Creoptix Wave system. CVA16 2A protease is used as a surrogate for the related enterovirus A71 (EV-A71) 2A protease in the pan-enteroviral drug discovery efforts by our collaborator, the AI-Driven Structure-Enabled Antiviral Platform (ASAP) Discovery Center, and was chosen as the target for OpenBind's first data release package. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged CVA16 2A protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- Open Access
- 20 July 2026
- Published by Springer Nature
Zika virus NS2B-NS3 protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Zika virus (ZIKV) NS2B-NS3 protease using the Creoptix Wave system. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged ZIKV NS2B-NS3 protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- 20 July 2026
- Published by Springer Nature
Open AccessZika virus NS2B-NS3 protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Zika virus (ZIKV) NS2B-NS3 protease using the Creoptix Wave system. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged ZIKV NS2B-NS3 protease was captured on the streptavidin-coated chip surface. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- Open Access
- 1 May 2026
- Published by Springer Nature
Assessing protein crystal tolerance of chemistry reagents for HT-crystallographic screening v2
This protocol describes the testing of how protein crystals survive exposure to organic chemistry reagents and solvents, with the purpose of reducing crystal attrition prior to high-throughput crystallographic screening of ligands from crude reaction mixtures containing the reagents. A step-by-step description is included, describing how to complete this process using the XChem laboratory at Diamond Light Source and the Protein Crystallisation Facility at the Research Complex at Harwell. The data analysis cut-offs, rationale, and GitHub repo for the code utilised during analysis are included. This version updates the old spreadsheet-based analysis with a Python program using pandas dataframes, XtalControl. (v.02 at time of writing) https://github.com/xchem/XtalControl
- 1 May 2026
- Published by Springer Nature
Open AccessAssessing protein crystal tolerance of chemistry reagents for HT-crystallographic screening v2
This protocol describes the testing of how protein crystals survive exposure to organic chemistry reagents and solvents, with the purpose of reducing crystal attrition prior to high-throughput crystallographic screening of ligands from crude reaction mixtures containing the reagents. A step-by-step description is included, describing how to complete this process using the XChem laboratory at Diamond Light Source and the Protein Crystallisation Facility at the Research Complex at Harwell. The data analysis cut-offs, rationale, and GitHub repo for the code utilised during analysis are included. This version updates the old spreadsheet-based analysis with a Python program using pandas dataframes, XtalControl. (v.02 at time of writing) https://github.com/xchem/XtalControl
- Open Access
- 14 April 2026
- Published by Springer Nature
Assessing protein crystal tolerance of chemistry reagents for HT-crystallographic screening v2
This protocol describes the testing of how protein crystals survive exposure to organic chemistry reagents and solvents, with the purpose of reducing crystal attrition prior to high-throughput crystallographic screening of ligands from crude reaction mixtures containing the reagents. A step-by-step description is included, describing how to complete this process using the XChem laboratory at Diamond Light Source and the Protein Crystallisation Facility at the Research Complex at Harwell. The data analysis cutoffs, rationale, and the spreadsheet used during analysis are also included within the attachments.
- 14 April 2026
- Published by Springer Nature
Open AccessAssessing protein crystal tolerance of chemistry reagents for HT-crystallographic screening v2
This protocol describes the testing of how protein crystals survive exposure to organic chemistry reagents and solvents, with the purpose of reducing crystal attrition prior to high-throughput crystallographic screening of ligands from crude reaction mixtures containing the reagents. A step-by-step description is included, describing how to complete this process using the XChem laboratory at Diamond Light Source and the Protein Crystallisation Facility at the Research Complex at Harwell. The data analysis cutoffs, rationale, and the spreadsheet used during analysis are also included within the attachments.
- Open Access
- 31 March 2026
- Published by Springer Nature
Coxsackievirus A16 2A protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against coxsackievirus A16 (CVA16) 2A protease using the Creoptix Wave system. CVA16 2A protease is used as a surrogate for the related enterovirus A71 (EV-A71) 2A protease in the pan-enteroviral drug discovery efforts by our collaborator, the AI-Driven Structure-Enabled Antiviral Platform (ASAP) Discovery Center, and was chosen as the target for OpenBind's first data release package. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged CVA16 2A protease was captured on the streptavidin-coated chip surface via biotinylation. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- 31 March 2026
- Published by Springer Nature
Open AccessCoxsackievirus A16 2A protease binding assay for compound screening using grating-coupled interferometry v1
This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against coxsackievirus A16 (CVA16) 2A protease using the Creoptix Wave system. CVA16 2A protease is used as a surrogate for the related enterovirus A71 (EV-A71) 2A protease in the pan-enteroviral drug discovery efforts by our collaborator, the AI-Driven Structure-Enabled Antiviral Platform (ASAP) Discovery Center, and was chosen as the target for OpenBind's first data release package. Grating-coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fragments, etc.) with enhanced sensitivity. Biotin-tagged CVA16 2A protease was captured on the streptavidin-coated chip surface via biotinylation. This immobilisation technique provides oriented and active protein immobilisation for binding assays and can be applied to different protein targets. Binding analysis was performed with the Repeated Analyte Pulses of Increasing Duration (RAPID) method, which involves the injection of samples at a single concentration with varied association times. Kinetic parameters were obtained from the Creoptix Wave software (v 4.5.18) and the in-house developed, open-source, Python-based tool 'SensoFit' (xchem/sensofit).
- Open Access
- 30 March 2026
- Published by Springer Nature
Assessing protein crystal tolerance of chemistry reagents for HT-crystallographic screening. v1
This protocol describes the testing of how protein crystals survive exposure to organic chemistry reagents and solvents, with the purpose of reducing crystal attrition prior to high-throughput crystallographic screening of ligands from crude reaction mixtures containing the reagents. A step-by-step description is included, describing how to complete this process using the XChem laboratory and Protein Crystallisation Facility at Diamond Light Source. The data analysis cutoffs, rationale, and the spreadsheet used during analysis are also included within the attachments.
- 30 March 2026
- Published by Springer Nature
Open AccessAssessing protein crystal tolerance of chemistry reagents for HT-crystallographic screening. v1
This protocol describes the testing of how protein crystals survive exposure to organic chemistry reagents and solvents, with the purpose of reducing crystal attrition prior to high-throughput crystallographic screening of ligands from crude reaction mixtures containing the reagents. A step-by-step description is included, describing how to complete this process using the XChem laboratory and Protein Crystallisation Facility at Diamond Light Source. The data analysis cutoffs, rationale, and the spreadsheet used during analysis are also included within the attachments.
- Open Access
- 24 November 2024
- Published by Wiley in Applied Research
- Vol. 4 (1)
Accelerating Drug Discovery With High‐Throughput Crystallographic Fragment Screening and Structural Enablement
Fragment‐based drug discovery is a well‐established method for the identification of chemical starting points for development into clinical candidates. Historically, crystallographic fragment screening was perceived to be low‐throughput and time consuming. However, thanks to advances in synchrotron capabilities and the introduction of dedicated facilities, such as the XChem platform at Diamond Light Source, there have been substantial improvements in throughput and integration between sample preparation, data collection and hit identification. Herein we share our experiences of establishing a crystallographic fragment screening facility, our learnings from operating a user programme for ten years and our perspective on applying structural enablement to rapidly progress initial fragment hits to lead‐like molecules.
- 24 November 2024
- Published by Wiley in Applied Research
- Vol. 4 (1)
Open AccessAccelerating Drug Discovery With High‐Throughput Crystallographic Fragment Screening and Structural Enablement
Fragment‐based drug discovery is a well‐established method for the identification of chemical starting points for development into clinical candidates. Historically, crystallographic fragment screening was perceived to be low‐throughput and time consuming. However, thanks to advances in synchrotron capabilities and the introduction of dedicated facilities, such as the XChem platform at Diamond Light Source, there have been substantial improvements in throughput and integration between sample preparation, data collection and hit identification. Herein we share our experiences of establishing a crystallographic fragment screening facility, our learnings from operating a user programme for ten years and our perspective on applying structural enablement to rapidly progress initial fragment hits to lead‐like molecules.